Dextromethorphan Hydrobromide and Quinidine Sulphate
Dextromethorphan Hydrobromide and Quinidine Sulphate is listed in the FDA National Drug Code directory with 2 NDC codes, marketed under brand name including Dextromethorphan Hydrobromide and Quinidine Sulphate. Available dosage form: capsule.
Drug details
- Generic Name
- Dextromethorphan Hydrobromide and Quinidine Sulphate
- Brand Names
- Dextromethorphan Hydrobromide and Quinidine Sulphate
- Application Number
- ANDA204196
- Sponsor
- Sun Pharmaceutical Industries, Inc.
- NDC Codes
- 2
- Dosage Forms
- CAPSULE
- Routes
- ORAL
- Active Ingredients
- DEXTROMETHORPHAN HYDROBROMIDE, QUINIDINE SULFATE
Indications and Usage
1 INDICATIONS AND USAGE Dextromethorphan hydrobromide and quinidine sulfate capsules are indicated for the treatment of pseudobulbar affect (PBA). PBA occurs secondary to a variety of otherwise unrelated neurologic conditions, and is characterized by involuntary, sudden, and frequent episodes of laughing and/or crying. PBA episodes typically occur out of proportion or incongruent to the underlying emotional state. PBA is a specific condition, distinct from other types of emotional lability that may occur in patients with neurological disease or injury. Dextromethorphan hydrobromide and quinidine sulfate capsules is a combination product containing dextromethorphan hydrobromide (an uncompetitive NMDA receptor antagonist and sigma-1 agonist) and quinidine sulfate (a CYP450 2D6 inhibitor) indicated for the treatment of pseudobulbar affect (PBA). ( 1 )